文献速递妇科

免疫检查点抑制剂治疗复发性卵巢透明细胞癌:韩国多中心研究的真实世界结局

Immune checkpoint inhibitors for recurrent ovarian clear cell carcinoma: Real-world outcomes from a Korean multicenter study.
PubMed 文献 · Gynecol Oncol · 2025-11-08

该研究回顾性分析了韩国3家机构2015至2024年间66例接受免疫检查点抑制剂(ICI)治疗的复发性卵巢透明细胞癌(OCCC)患者,评估疗效与安全性。结果显示最佳客观缓解率(ORR)为6.3%,疾病控制率(DCR)为21.9%,中位无进展生存期(PFS)2.6个月,中位总生存期(OS)7.8个月;ICI耐受性良好但抗肿瘤活性有限,作者认为需进一步研究明确其治疗角色。

要点

  • 复发性OCCC患者接受ICI治疗的最佳ORR为6.3%,DCR为21.9%。
  • 中位随访26.7个月,中位PFS为2.6个月,中位OS为7.8个月。
  • 1-3级治疗相关不良事件发生于6例(40.9%),未见4级或5级事件。

核心结论

  • ICI在复发性OCCC中耐受性良好,但抗肿瘤活性有限;作者认为需进一步研究明确ICI在该场景中的治疗角色。

研究设计与样本

  • 回顾性研究,纳入韩国3家机构2015至2024年间接受ICI治疗的复发性OCCC患者66例。

主要发现

  • 66例中39例(59.1%)接受帕博利珠单抗,15例(22.7%)接受纳武利尤单抗,9例(13.7%)接受度伐利尤单抗,3例(4.5%)接受阿维鲁单抗。
  • 诊断时中位年龄51.0岁(范围27-86),既往系统治疗中位线数为3线(范围1-10),46例(69.7%)既往接受过抗血管生成药物。
  • 最佳ORR为6.3%,4例达部分缓解;DCR为21.9%,包括4例部分缓解和10例疾病稳定。
  • 中位随访26.7个月,中位PFS为2.6个月,中位OS为7.8个月。
  • 1-3级治疗相关不良事件发生于6例(40.9%),未观察到4级或5级治疗相关不良事件。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Recurrent ovarian clear cell carcinoma (OCCC) is an aggressive, chemotherapy-resistant subtype with poor prognosis. Given its distinct biology, immune checkpoint inhibitors (ICIs) may offer therapeutic potential. This study aimed to assess the real-world efficacy and safety of ICIs in patients with recurrent OCCC in South Korea. METHODS: We retrospectively investigated the recurrent OCCC patients who treated with ICI at 3 institutions in Korea between 2015 and 2024. We evaluated the objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS) and safety. RESULTS: A total of 66 patients with recurrent OCCC were included in the study. Among them, 39 patients (59.1 %) received pembrolizumab, 15 (22.7 %) received nivolumab, 9 (13.7 %) received durvalumab, and 3 (4.5 %) received avelumab. The median age at diagnosis was 51.0 years (range, 27-86), and patients had received a median of 3 prior lines of systemic therapy (range, 1-10), with 46 patients (69.7 %) having previously received anti-angiogenic agents. The best ORR was 6.3 %, with 4 patients achieving partial responses. The DCR was 21.9 %, including 4 partial responses and 10 cases of stable disease. After a median follow-up of 26.7 months, the median PFS was 2.6 months, and the median OS was 7.8 months. Treatment-related adverse events (TRAEs) of grade 1-3 occurred in 6 patients (40.9 %). No grade 4 or 5 TRAEs were observed. CONCLUSIONS: Although ICIs were well tolerated, their antitumor activity in recurrent OCCC was limited. Further studies are warranted to clarify the therapeutic role of ICIs in this setting.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Chung YE, Kim SI, Noh JJ, et al. Immune checkpoint inhibitors for recurrent ovarian clear cell carcinoma: Real-world outcomes from a Korean multicenter study. Gynecol Oncol. 2025. PMID: 41206981. doi:10.1016/j.ygyno.2025.10.040

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。